Application of selective CDK4/6 inhibitors in solid cancers therapy

Abstract

Cyclin-dependent kinase (CDK) inhibitors have been approved for the treatment of ER+ /HER2- advanced breast cancer, and preclinical study and clinical trials are under way for multiple solid cancers. CDK4/6 inhibitors have shown good efficacy for human solid cancers, and it′s future development direction are biomarkers, drug resis-tance and combined therapy in the future. Key words: Neoplasms; Cyclin-dependent kinases; Therapeutics; Cell cycle